



Antibody Drug Conjugates

Guest Editor:

Dr. R. James Christie

Department of Antibody
Discovery and Protein
Engineering, MedImmune, One
MedImmune Way, Gaithersburg,
MD 20878, USA

Deadline for manuscript
submissions:

closed (15 December 2017)

Message from the Guest Editor

Dear Colleagues,

Antibody drug conjugates (ADCs) are a promising class of biotherapeutics for the treatment of diseases, such as cancer. Pairing potent drugs with antibodies through covalent attachment generates a unique therapeutic molecule, where the antibody provides cell-selectivity and extended serum half-life, while the drug provides a potent inhibitor of metabolism. “Piggybacking” potent small molecule drugs onto large antibody carriers has allowed new drugs to be used for cancer treatment (such as auristatins, tubulysins, PBDs, and duocarmycins) that present challenges as small molecule therapies alone. Recently fueled by the clinical success of Kadcyla and Adcetris.

This Special Issue of *Antibodies* focuses on recent advances in ADC technology, including drug-linker design, warhead selection, conjugation approaches, antibody engineering, target selection, clinical manifestation, and other aspects related to ADCs.

Dr. R. James (Jim) Christie

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: CiteScore - Q2 (*Drug Discovery*)

Contact Us

Antibodies Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
X@Antibodies_MDPI